Verona Pharma PLC (VRNA)
| Market Cap | 265.62M |
| Revenue (ttm) | 40.00M |
| Net Income (ttm) | -59.12M |
| Shares Out | 60.37M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,752 |
| Open | 4.13 |
| Previous Close | 4.18 |
| Day's Range | 4.06 - 4.40 |
| 52-Week Range | 3.41 - 7.87 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 21.42 (+386.8%) |
| Earnings Date | May 3, 2022 |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing en...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for VRNA stock is "Buy." The 12-month stock price forecast is 21.42, which is an increase of 386.82% from the latest price.
News
Verona Pharma to Present at Jefferies Healthcare Conference
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company ov...
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at...
Abstract supports ongoing Phase 3 program and planned NDA submission Abstract supports ongoing Phase 3 program and planned NDA submission
Verona Pharma Announces May 2022 Investor Conference Participation
LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces tha...
James Brady Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr....
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line Data Expected in the Third Quarter of 2022 Top-line Data Expected in the Third Quarter of 2022
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Study Supports Ongoing Phase 3 Program and Planned NDA Submission Study Supports Ongoing Phase 3 Program and Planned NDA Submission
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021
Verona Pharma Announces November 2021 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congr...
Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacok...
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program on track to report top-line data in 2022
Verona Pharma Announces August 2021 Virtual Investor Conference Participation
LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that ...
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2...
Posters highlight ensifentrine's safety profile and its potential to improve lung function and quality of life irrespective of COPD severity Posters highlight ensifentrine's safety profile and its poten...
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces dat...